HUTCHMED (China) Limited (HCM) Stock Price & How to Invest

HUTCHMED (China) Limited trades on Nasdaq as ADSs under HCM, on the Hong Kong Stock Exchange as stock code 13, and on London's AIM market. It discovers and develops targeted oncology and immunology therapies in China and increasingly commercializes them globally through partners. Its marketed portfolio includes fruquintinib (sold as ELUNATE in China with Eli Lilly and as FRUZAQLA outside China with Takeda), surufatinib (SULANDA) for neuroendocrine tumors, and savolitinib (ORPATHYS) partnered with AstraZeneca. A separate Other Ventures segment, mainly prescription drug distribution in China, contributed ~$116 million of revenue in the first half of 2026 and is a lower-margin, non-innovative business that inflates headline revenue relative to the drug franchise.

The investment picture is defined by three things. First, the balance sheet: cash and short-term investments were ~$1.37 billion at June 30, 2026 against a market value of roughly $2.4 billion, so the operating business is capitalized at only about $1.2 billion. Second, the earnings profile is thin and partner-dependent: net income attributable to HUTCHMED was ~$15.9 million in the first half of 2026, against ~$455.0 million a year earlier, but that prior figure was almost entirely a one-off ~$416.3 million net gain on divesting 45% of Shanghai Hutchison Pharmaceuticals. Third, the narrative driver has shifted to the ATTC payload platforms: on September 3, 2026 HUTCHMED licensed HMPL-A830, a KRAS-EGFR conjugate, to GSK for ~$110 million upfront plus up to ~$1.185 billion in milestones, and the ADSs rose about 17% that day. That deal is the template management says it wants to repeat.

Most of HUTCHMED's product economics run through partners, so Takeda, Eli Lilly and AstraZeneca decisions on pricing, launch pace and promotion shape results more than HUTCHMED's own execution does. China pricing is set through the National Reimbursed Drug List process, where volume gains routinely come with steep price cuts, and the Other Ventures distribution segment is low margin and shrank 14% year over year. Clinical risk is concentrated: the SAFFRON and SANOVO savolitinib readouts, the sovleplenib NDAs and the ATTC dose escalations can each move the story sharply in either direction, and the FDA has previously rejected a HUTCHMED application (surufatinib in 2022), which cut the ADSs about 18% in a day. Governance and geopolitics add further uncertainty: CEO Dr Weiguo Su has been on a health-related leave of absence since August 2025 with CFO Johnny Cheng serving as acting CEO, the ADS structure (each ADS represents five ordinary shares) exposes holders to Hong Kong listing dynamics and currency, and US-China biotech policy including proposals targeting Chinese biotech partnerships remains an unresolved overhang. HUTCHMED's own interim filing states it is not aware of pending claims likely to have a material adverse effect, but past plaintiff-firm investigations show the litigation surface is real for a company with binary regulatory events.

14 analysts publish price targets on HCM, averaging $21.47 against a $14.09 price as of September 2026, or +52.4%. The published targets run from $11.10 to $40.40, a wide spread, and the ratings split 10 buy, 3 hold, 0 sell. Over the last six months there have been 0 raises and 2 cuts among the published actions. A price target is what an analyst published on a date, not a prediction, and sell-side ratings skew positive across the whole market.

Read the full HCM forecast and price target for the target table, the recent rating actions by firm, and how the consensus has shifted.

We give no verdict on HUTCHMED (China) Limited. Both cases are real, which is why the question is contested at all, so here is the strongest version of each.

The case for buying. ATTC platform licensing as the value unlock. The GSK agreement for HMPL-A830 announced in September 2026 put an external price on one preclinical-stage asset: ~$110 million upfront, up to ~$1.185 billion in development, regulatory and commercial milestones, and tiered royalties, with GSK taking worldwide rights outside mainland China, Hong Kong, Macau and Taiwan. The most optimistic published target, $40.40, assumes this works close to its best case.

The case against. Most of HUTCHMED's product economics run through partners, so Takeda, Eli Lilly and AstraZeneca decisions on pricing, launch pace and promotion shape results more than HUTCHMED's own execution does. The most pessimistic target, $11.10, is roughly what HCM is worth if this bites instead.

Read the full bull and bear case on HCM, including what would have to change to break either one. Walnut is not an investment adviser.

A simple financial snapshot. These are approximations and refresh quarterly; for current figures see HUTCHMED (China) Limited's investor relations page or your broker.

• Market capitalization: ~$2.4B (ADS ~$14, ~173M ADSs, each ADS = 5 ordinary shares)
• Revenue (TTM): ~$549M (FY2025 ~$548.5M; H1 2026 ~$278.3M vs ~$277.7M in H1 2025)
• Net income attributable (TTM): ~$18M (H1 2026 ~$15.9M; the ~$455M H1 2025 figure was mostly a one-off SHPL divestment gain)
• Cash and short-term investments: ~$1.37B at June 30, 2026, against ~$95M of bank borrowings
• Enterprise value / TTM revenue: ~$1.2B EV, roughly ~2.1x trailing revenue
• FY2026 company guidance: Oncology/Immunology consolidated revenue of ~$330M to ~$450M (reiterated July 2026)

The headline revenue number is misleading on its own because ~$116 million of first-half 2026 revenue came from the low-margin Other Ventures drug distribution segment rather than innovative medicines; the oncology and immunology franchise generated ~$162.3 million, of which ~$40.9 million was milestone, royalty and R&D service income including an ~$18.1 million payment from Eli Lilly. Profitability is genuine but slim, with R&D of ~$78.8 million in the half consuming most of the gross profit. Because net cash covers roughly half the market value, valuation multiples on the operating business look far lower than a screener showing price-to-sales on the consolidated figure would suggest.

Other names that sit close to HCM: same theme, named as a direct competitor, or held beside it in the same funds. Each entry says which. Worth a look if you are thinking about diversification within a thesis rather than concentration on one ticker.

There are three common ways to get HCM exposure. Buy shares (or fractional shares) directly at any major broker. Hold an ETF that includes it, which spreads the position across many companies. Or build it into a focused thematic portfolio, so HCM sits alongside other stocks that express the same thesis.

Walnut takes the portfolio route. Describe a thesis where HCM fits (for example “AI infrastructure” or “dividend-growth large-caps”) and the AI proposes 5 to 6 constituents with target weights. You review the plan and fund it through your own broker when you're ready.

New to this? Start with how to invest in stocks, see how to analyze a stock with AI, or compare the best AI stock analyzers.

HUTCHMED is an unusual hybrid, a profitable-on-paper China oncology company trading at a low enterprise value because of its ~$1.37 billion cash pile, with the equity case resting on ATTC licensing deals and 2026 and 2027 readouts rather than on current product sales.

Whether HCM is worth buying today depends more on your time horizon and what you already hold than on any single call. We walk through valuation, what would have to go right, and the risks in is HCM a buy or a sell?, and where the stock could go from here in the HCM stock forecast.

For income investors, whether HCM pays a dividend and how the payout looks is covered in does HCM pay a dividend? And to weigh HCM against a peer, read the full side-by-side comparisons: HCM vs ONC and HCM vs ZLAB.